Exelixis (NASDAQ:EXEL – Get Free Report) will likely be issuing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Exelixis to announce earnings of $0.8530 per share and revenue of $636.3960 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 5:00 PM ET.
Exelixis (NASDAQ:EXEL – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.12. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The firm had revenue of $610.81 million for the quarter, compared to analysts’ expectations of $607.51 million. During the same quarter last year, the company posted $0.55 EPS. The business’s quarterly revenue was up 10.0% on a year-over-year basis. On average, analysts expect Exelixis to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.
Exelixis Stock Performance
Shares of NASDAQ:EXEL opened at $53.03 on Monday. The firm has a market capitalization of $13.33 billion, a PE ratio of 17.62, a price-to-earnings-growth ratio of 1.53 and a beta of 0.44. Exelixis has a 52-week low of $33.76 and a 52-week high of $57.57. The firm has a fifty day moving average of $53.73 and a 200 day moving average of $47.61.
Insider Activity
Institutional Trading of Exelixis
A number of institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC lifted its holdings in Exelixis by 48.8% in the fourth quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock worth $598,647,000 after buying an additional 4,477,029 shares during the period. UBS Group AG grew its holdings in shares of Exelixis by 100.1% during the 3rd quarter. UBS Group AG now owns 2,655,069 shares of the biotechnology company’s stock worth $109,654,000 after acquiring an additional 1,328,087 shares during the period. Morgan Stanley raised its position in shares of Exelixis by 31.0% in the 4th quarter. Morgan Stanley now owns 4,206,656 shares of the biotechnology company’s stock worth $184,378,000 after acquiring an additional 995,949 shares in the last quarter. Bank of America Corp DE raised its position in shares of Exelixis by 38.2% in the 2nd quarter. Bank of America Corp DE now owns 2,638,666 shares of the biotechnology company’s stock worth $116,299,000 after acquiring an additional 728,956 shares in the last quarter. Finally, Voloridge Investment Management LLC lifted its stake in shares of Exelixis by 203.8% in the 4th quarter. Voloridge Investment Management LLC now owns 960,768 shares of the biotechnology company’s stock valued at $42,110,000 after purchasing an additional 644,495 shares during the period. Hedge funds and other institutional investors own 85.27% of the company’s stock.
Analyst Ratings Changes
A number of research firms have recently issued reports on EXEL. Morgan Stanley upped their price objective on Exelixis from $50.00 to $53.00 and gave the stock an “equal weight” rating in a report on Thursday, July 23rd. Barclays raised their price objective on Exelixis from $45.00 to $49.00 and gave the company an “equal weight” rating in a report on Tuesday, July 14th. TD Cowen boosted their target price on Exelixis from $51.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Wall Street Zen raised Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Royal Bank Of Canada increased their price target on shares of Exelixis from $43.00 to $46.00 and gave the company a “sector perform” rating in a research report on Tuesday, July 7th. Eight analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $49.29.
Exelixis Company Profile
Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.
The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.
Read More
- Five stocks we like better than Exelixis
- 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story
- AbbVie Quietly Solved Its Biggest Problem—Now What?
- Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade
- Strategy’s Structural Strength: Hidden in a $8 Billion Illusion
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.
